IDEAYA Biosciences, Inc.
IDYA
Classement en actions
#4479
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Prix de l'action
$35.80
Capitalisation boursière
$3.45B
Changement (1 jour)
1.24%
Changement (1 an)
22.60%
Pays
US
Échange IDEAYA Biosciences, Inc. (IDYA)
Catégorie
Healthcare
Revenus pour IDEAYA Biosciences, Inc. (IDYA)
Revenus en Jun 2026 TTM : $234.13M
Selon les derniers rapports financiers de IDEAYA Biosciences, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $234.13M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $23.39M une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $50.93M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour IDEAYA Biosciences, Inc. de 2017 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $234.13M | 3,244.67% |
| 2024 | $7.00M | -70.07% |
| 2023 | $23.39M | -54.08% |
| 2022 | $50.93M | 82.28% |
| 2021 | $27.94M | 43.01% |
| 2020 | $19.54M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 5,292.07% |
US
|
|
| $2.23B | 851.62% |
US
|
|
| $15.74B | 6,624.70% |
AU
|
|
| $6.02B | 2,471.80% |
NL
|
|
| - | - |
CH
|
